{
  "meta": {
    "title": "Mid_Day_Module_Mixed_Bag-6",
    "url": "https://brainandscalpel.vercel.app/mid-day-module-mixed-bag-6-21be6c61.html",
    "scrapedAt": "2025-11-29T18:15:25.451Z"
  },
  "questions": [
    {
      "id": 31819,
      "choices": [
        {
          "id": 127146,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Arrhythmias </span></span></p>"
        },
        {
          "id": 127147,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Confusion </span></span></p>"
        },
        {
          "id": 127148,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hypothermia </span></span></p>"
        },
        {
          "id": 127149,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pupillary dilation</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 45-year-old patient with a history of depression was started on amitriptyline, a tricyclic antidepressant (TCA). The patient was later found unconscious at home and brought to the emergency department. On examination, the patient shows signs of arrhythmias, confusion, and pupillary dilation. Which of the following does NOT suggest TCA poisoning?</span></span></p>",
      "unique_key": "Q9253538",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696030,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) Hypothermia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hypothermia is NOT typically associated with TCA poisoning. In fact, hyperthermia may occur due to anticholinergic effects leading to decreased sweating and heat dissipation.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tricyclic antidepressant (TCA) poisoning can lead to a variety of clinical manifestations, primarily due to their anticholinergic, sodium channel-blocking, and alpha-adrenergic blocking effects. The key features in this case would be:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Arrhythmias:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">TCAs block sodium channels, leading to cardiac conduction delays, which can manifest as arrhythmias. They can also cause QT prolongation, predisposing to torsades de pointes.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Therefore, arrhythmias are a common and significant feature of TCA poisoning.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Confusion:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The anticholinergic effects of TCAs can lead to mental status changes, including confusion, agitation, and even delirium.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Confusion is a typical presentation in TCA overdose.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Pupillary Dilation:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Anticholinergic effects also include pupillary dilation (mydriasis) due to paralysis of the iris sphincter muscle.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pupillary dilation is often observed in TCA toxicity.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hypothermia is not a typical feature of tricyclic antidepressant (TCA) poisoning, whereas arrhythmias, confusion, and pupillary dilation are common clinical manifestations.</span></span></p>",
      "correct_choice_id": 127148,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31811,
      "choices": [
        {
          "id": 127114,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Oprelvekin </span></span></p>"
        },
        {
          "id": 127115,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fostamatinib </span></span></p>"
        },
        {
          "id": 127116,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Eltrombopag </span></span></p>"
        },
        {
          "id": 127117,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Bosutinib</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient presents with widespread purpura and easy bruising. Laboratory tests reveal a significantly low platelet count with normal hemoglobin and white blood cell count, indicating a diagnosis of isolated thrombocytopenia. The patient has no prior history of autoimmune disorders or recent viral infections. Considering these symptoms and diagnosis, which tyrosine kinase inhibitor would be appropriate for this patient? (INICET NOV 2023)</span></span></p>",
      "unique_key": "Q8292950",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696027,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans B) Fostamatinib.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fostamatinib is the suitable choice in this case. It is a tyrosine kinase inhibitor used specifically for the treatment of chronic immune thrombocytopenia (ITP), a condition characterized by isolated thrombocytopenia, which manifests as low platelet counts leading to symptoms like purpura and easy bruising. It operates by inhibiting spleen tyrosine kinase (Syk), thereby reducing the destruction of platelets and helping to increase the platelet count.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Oprelvekin:</strong> Oprelvekin is not a tyrosine kinase inhibitor; it is a thrombopoietic growth factor used to increase platelet production, particularly in cases of chemotherapy-induced thrombocytopenia, rather than isolated thrombocytopenia without a clear underlying cause.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Eltrombopag:</strong> Eltrombopag is a thrombopoietin receptor agonist, not a tyrosine kinase inhibitor. It is used to treat thrombocytopenia, including ITP, but through a different mechanism - stimulating platelet production in the bone marrow.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Bosutinib:</strong> Bosutinib is a tyrosine kinase inhibitor; however, its primary use is in treating chronic myelogenous leukemia (CML), not isolated thrombocytopenia or ITP. It targets the BCR-ABL tyrosine kinase, which is not involved in the pathology of ITP.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fostamatinib is a tyrosine kinase inhibitor specifically used for treating chronic immune thrombocytopenia (ITP) by inhibiting spleen tyrosine kinase (Syk) to reduce platelet destruction and increase platelet count.</span></span></p>",
      "correct_choice_id": 127115,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31812,
      "choices": [
        {
          "id": 127118,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Skin rash </span></span></p>"
        },
        {
          "id": 127119,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hepatitis with raised GGT</span></span></p>"
        },
        {
          "id": 127120,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hyponatremia </span></span></p>"
        },
        {
          "id": 127121,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Blood dyscrasias</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">When comparing oxcarbazepine and carbamazepine, which of the following adverse effects is more commonly associated with oxcarbazepine?</span></span></p>",
      "unique_key": "Q6928742",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696028,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) Hyponatremia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hyponatremia, or low sodium levels in the blood, is a known side effect of oxcarbazepine and is more commonly seen with this drug compared to carbamazepine. Oxcarbazepine can cause an inappropriate secretion of antidiuretic hormone (SIADH), leading to water retention and a subsequent dilution of sodium in the body. While both oxcarbazepine and carbamazepine can cause hyponatremia, the incidence is higher with oxcarbazepine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Skin rash:</strong> Skin rashes can occur with both oxcarbazepine and carbamazepine. However, the incidence of skin rash is not significantly higher with oxcarbazepine compared to carbamazepine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Hepatitis with raised GGT:</strong> Hepatitis and elevated GGT levels can occur with carbamazepine, but they are not particularly more common with oxcarbazepine. Both drugs can affect liver enzyme levels, but this is not a distinguishing factor between the two in terms of commonality.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Blood dyscrasias:</strong> Blood dyscrasias, including agranulocytosis and aplastic anemia, are serious but rare side effects of both oxcarbazepine and carbamazepine. There is no significant difference in the incidence of these effects between the two drugs.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hyponatremia is more commonly associated with oxcarbazepine compared to carbamazepine, often due to the inappropriate secretion of antidiuretic hormone (SIADH) leading to water retention and dilution of sodium.</span></span></p>",
      "correct_choice_id": 127120,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54794,
      "choices": [
        {
          "id": 218641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">NREM 2</span></span></span></p>"
        },
        {
          "id": 218642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">NREM 3</span></span></span></p>"
        },
        {
          "id": 218643,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">NREM 4</span></span></span></p>"
        },
        {
          "id": 218644,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">&nbsp;REM</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the stage of sleep denoted by the arrow: (INICET MAY 2024)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-152214.png\" style=\"height:193px; width:400px\" /></p>",
      "unique_key": "Q1902247",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696046,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) REM</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The stage of sleep indicated by the arrow is REM (Rapid Eye Movement) sleep. This can be identified based on the specific patterns observed in the EEG (Electroencephalogram), EMG (Electromyogram), and EOG (Electrooculogram) readings:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/whatsapp-image-2024-08-26-at-21214-pm.jpeg\" style=\"height:220px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">EEG</span></strong><span style=\"font-size:12.0pt\">: The EEG during REM sleep shows low-amplitude, high-frequency waves that are similar to the wakeful state. This pattern is characteristic of REM sleep and is often described as &quot;sawtooth&quot; waves.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">EMG</span></strong><span style=\"font-size:12.0pt\">: The EMG during REM sleep shows a flat line, indicating muscle atonia. This muscle atonia is a defining feature of REM sleep, where most of the body&#39;s voluntary muscles are temporarily paralyzed. This prevents the sleeper from acting out their dreams.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">EOG</span></strong><span style=\"font-size:12.0pt\">: The EOG during REM sleep shows rapid movements of the eyes, which is where REM sleep gets its name. These rapid eye movements are indicative of the intense brain activity occurring during this stage, despite the body&#39;s overall lack of movement.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In contrast, non-REM (NREM) sleep stages (including NREM 2, 3, and 4) show different patterns:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NREM stages generally have higher amplitude, lower frequency EEG patterns.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Muscle tone is reduced but not absent as in REM sleep.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eye movements are either slow or absent, depending on the specific NREM stage.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. NREM 2</span></strong><span style=\"font-size:12.0pt\">: This stage of sleep is characterized by sleep spindles and K-complexes on the EEG, with reduced but not absent muscle tone and minimal eye movement. The patterns described in the question do not match this stage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. NREM 3</span></strong><span style=\"font-size:12.0pt\">: Known as slow-wave sleep or deep sleep, NREM 3 is characterized by high-amplitude, low-frequency delta waves on the EEG. Muscle tone is decreased but not completely absent, and there is minimal to no eye movement. The pattern described does not correspond to NREM 3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. NREM 4</span></strong><span style=\"font-size:12.0pt\">: Often combined with NREM 3 in the modern classification, this stage is also characterized by delta waves, reduced muscle tone, and lack of eye movement. The described pattern is inconsistent with this stage as well.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">REM sleep is characterized by low-amplitude, high-frequency EEG waves, muscle atonia as shown in the EMG, and rapid eye movements as shown in the EOG. Recognizing these patterns is crucial for correctly identifying REM sleep, which is a critical stage for processes like memory consolidation and emotional regulation.</span></span></span></p>",
      "correct_choice_id": 218644,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54793,
      "choices": [
        {
          "id": 218637,
          "text": "<p><span style=\"font-size:12.0pt;\">Norepinephrine</span></p>"
        },
        {
          "id": 218638,
          "text": "<p><span style=\"font-size:12.0pt;\">Epinephrine</span></p>"
        },
        {
          "id": 218639,
          "text": "<p><span style=\"font-size:12.0pt;\">Dopamine</span></p>"
        },
        {
          "id": 218640,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetylcholine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">SA node release following in response to increasing blood pressure:</span></p>",
      "unique_key": "Q5495734",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696045,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Acetylcholine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">When blood pressure increases, baroreceptors (pressure-sensitive receptors located in the carotid sinus and aortic arch) are activated. These receptors detect the rise in blood pressure and send signals to the cardiovascular center in the medulla oblongata, specifically to the cardio-inhibitory center (CIC). Activation of the CIC results in the stimulation of the vagus nerve, which releases acetylcholine at the SA node of the heart. Acetylcholine acts on muscarinic receptors to decrease the heart rate (a process known as bradycardia), helping to lower the blood pressure back to normal levels.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Norepinephrine</strong>: Norepinephrine is typically released in response to a decrease in blood pressure, not an increase. It is a sympathetic neurotransmitter that increases heart rate and contractility, which would raise blood pressure, not lower it.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Epinephrine</strong>: Similar to norepinephrine, epinephrine is released by the adrenal medulla in response to stress or low blood pressure. It increases heart rate, myocardial contractility, and peripheral vasoconstriction, which elevates blood pressure. Therefore, it is not released in response to increased blood pressure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Dopamine</strong>: Dopamine has various effects depending on the dose but is generally associated with increasing blood pressure and cardiac output. It is not involved in the reflex reduction of heart rate in response to high blood pressure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Acetylcholine is released from the vagus nerve at the SA node in response to increased blood pressure, resulting in a decrease in heart rate (bradycardia) as part of the baroreceptor reflex.</span></p>",
      "correct_choice_id": 218640,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31802,
      "choices": [
        {
          "id": 127078,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Lamotrigine </span></span></p>"
        },
        {
          "id": 127079,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Carbamazepine </span></span></p>"
        },
        {
          "id": 127080,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate </span></span></p>"
        },
        {
          "id": 127081,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Topiramate</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a mood disorder has been on medication and presents with new-onset liver dysfunction and hyperammonemia. Which of the following medications is most likely responsible for these findings?</span></span></p>",
      "unique_key": "Q9424845",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696042,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) Valproate</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate (valproic acid) is an anticonvulsant and mood-stabilizing drug used to treat seizures, bipolar disorder, and to prevent migraine headaches. However, it is known to potentially cause hepatotoxicity (liver dysfunction) and hyperammonemia, especially when used in combination with other anticonvulsants or in patients with preexisting liver disease. Hepatotoxicity may be dose-dependent or idiosyncratic, and its risk is increased in the first six months of treatment, with higher doses, and with multiple antiepileptic drug regimens. Hyperammonemia occurs due to valproate&rsquo;s interference with the urea cycle in the liver.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong> <strong>Lamotrigine:</strong> While lamotrigine can have side effects, it is more commonly associated with skin rashes and is not known to cause liver dysfunction and hyperammonemia as a typical adverse effect.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong> <strong>Carbamazepine:</strong> Carbamazepine can cause liver dysfunction but is less likely to cause hyperammonemia. It is more commonly associated with blood dyscrasias such as agranulocytosis and aplastic anemia.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Topiramate:</strong> This medication is not commonly associated with liver dysfunction or hyperammonemia. It has other side effects, such as weight loss, paresthesias, and cognitive slowing, but liver issues are not typically seen.</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Therefore, in the context of a patient with mood disorder presenting with liver dysfunction and hyperammonemia, valproate is the most likely cause among the options provided.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate can cause hepatotoxicity and hyperammonemia, making it the most likely culprit in patients presenting with these conditions while on medication for mood disorders.</span></span></p>",
      "correct_choice_id": 127080,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31823,
      "choices": [
        {
          "id": 127162,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hydrocortisone </span></span></p>"
        },
        {
          "id": 127163,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sodium bicarbonate </span></span></p>"
        },
        {
          "id": 127164,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Insulin </span></span></p>"
        },
        {
          "id": 127165,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hypertonic saline</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient was brought to the emergency department in an unconscious state. The patient is dehydrated and the blood pressure of the patient is 90/60 mm Hg. Laboratory investigations revealed the serum potassium level of 6.0 mEq/L, sodium level of 129 mEq/L, and blood glucose level of 40 mg/dL. The patient has a history of rheumatoid arthritis (RA) for which he was prescribed medication by a local physician; however, the patient abruptly discontinued the medication a few weeks ago. Based on the clinical presentation and laboratory findings, which of the following drugs should be administered as a life-saving measure to treat this patient?</span></span></p>",
      "unique_key": "Q5507630",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696033,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Hydrocortisone</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hydrocortisone is indicated as it would treat adrenal insufficiency. It would help to correct hypotension, hyperkalemia, hyponatremia, and hypoglycemia by replacing the deficient cortisol.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The clinical presentation of hypotension, hyperkalemia, hyponatremia, dehydration, and hypoglycemia in a patient who has suddenly stopped taking medication for RA (potentially a corticosteroid) suggests the possibility of adrenal insufficiency or Addisonian crisis. This is particularly likely if the medication the patient was taking for RA was a corticosteroid, which is common in the management of RA.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Sodium bicarbonate: </strong>Sodium bicarbonate is used to treat metabolic acidosis, which is not indicated in this case as there is no mention of acidosis in the given scenario.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Insulin: </strong>Insulin is used in the treatment of hyperkalemia to drive potassium into cells, but it would not address the underlying adrenal insufficiency and could potentially worsen the hypoglycemia.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Hypertonic saline: </strong>Hypertonic saline is used to treat severe hyponatremia, which is not present in this case, as the sodium level is within normal limits.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hydrocortisone is the drug of choice for treating adrenal insufficiency or Addisonian crisis, which can present with hypotension, hyperkalemia, hyponatremia, dehydration, and hypoglycemia, especially in patients with a history of corticosteroid use who abruptly discontinue their medication.</span></span></p>",
      "correct_choice_id": 127162,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31800,
      "choices": [
        {
          "id": 127070,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Aspergillus niger: Voriconazole </span></span></span></p>"
        },
        {
          "id": 127071,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Aspergillus fumigatus: Micafungin </span></span></span></p>"
        },
        {
          "id": 127072,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Candida glabrata: Amphotericin B </span></span></span></p>"
        },
        {
          "id": 127073,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Candida krusei: Fluconazole</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Which of the following organism is intrinsically resistant to the given drug? </span></span></span></p>",
      "unique_key": "Q1458230",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696040,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"color:#343541\"><strong>Ans. D)</strong>&nbsp;</span><span dir=\"ltr\" lang=\"PT-BR\" style=\"color:#343541\"><strong>Candida krusei: Fluconazole</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Candida krusei is known to have intrinsic resistance to fluconazole, which means that this organism generally does not respond to treatment with fluconazole. This is due to a combination of mechanisms including alterations in the target enzyme lanosterol 14-&alpha;-demethylase, efflux pump activity, and changes in membrane sterols. Therefore, for infections caused by Candida krusei, alternative antifungal agents such as amphotericin B, echinocandins, or voriconazole are typically considered.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">In the clinical setting, the intrinsic resistance of Candida krusei to fluconazole is significant, as fluconazole is often used as a first-line agent for the treatment of Candida infections. The presence of Candida krusei may therefore necessitate a shift in the standard therapeutic approach and prompt the use of different antifungal therapy.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"color:#343541\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option </strong><span style=\"color:#343541\"><strong>A.</strong>&nbsp;</span><span style=\"color:#343541\"><strong>Aspergillus niger: Voriconazole</strong> Voriconazole is a broad-spectrum antifungal that is effective against most species of Aspergillus, including Aspergillus niger. It is often used as a first-line treatment for invasive aspergillosis. Therefore, Aspergillus niger is not intrinsically resistant to voriconazole.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option <span style=\"color:#343541\">B. Aspergillus fumigatus: Micafungin</span></strong><span style=\"color:#343541\"> Aspergillus fumigatus is generally susceptible to micafungin. Micafungin belongs to the echinocandin class of antifungal drugs, which are effective against most Aspergillus species, but echinocandins are not the first choice for the treatment of aspergillosis. They are typically used as second-line agents or in combination therapy for Aspergillus infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option </strong><span style=\"color:#343541\"><strong>C.</strong>&nbsp;</span><span style=\"color:#343541\"><strong>Candida glabrata: Amphotericin B</strong> Candida glabrata can be susceptible to amphotericin B, but it is known for having a dose-dependent sensitivity or a reduced susceptibility. Some strains may show resistance, but this is not considered intrinsic resistance. Instead, amphotericin B resistance in C. glabrata can be due to acquired mechanisms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/30/screenshot-2023-12-30-111101.jpg\" style=\"height:391px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"color:#343541\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Candida krusei is intrinsically resistant to fluconazole, necessitating the use of alternative antifungal agents for treatment.</span></span></p>",
      "correct_choice_id": 127073,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31810,
      "choices": [
        {
          "id": 127110,
          "text": "<p><span style=\"font-size:12pt;\">5-Aminosalicylic acid</span></p>"
        },
        {
          "id": 127111,
          "text": "<p><span style=\"font-size:12pt;\">5-Fluorouracil</span></p>"
        },
        {
          "id": 127112,
          "text": "<p><span style=\"font-size:12pt;\">Budesonide</span></p>"
        },
        {
          "id": 127113,
          "text": "<p><span style=\"font-size:12pt;\">6-Mercaptopurine</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A patient with ulcerative colitis is experiencing three episodes of bleeding in stools per day but is otherwise stable. What is the appropriate treatment for this patient? (INICET NOV 2023)</span></p>",
      "unique_key": "Q5712191",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696026,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) 5-Aminosalicylic acid.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">5-Aminosalicylic acid (5-ASA) is the first-line treatment for mild to moderate ulcerative colitis, especially in a stable patient who is experiencing active symptoms like bleeding. It works as an anti-inflammatory agent in the colon and is effective in inducing and maintaining remission.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. 5-Fluorouracil:</strong> This is a chemotherapeutic agent and is not used for treating ulcerative colitis. It's primarily used in cancer treatment.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Budesonide:</strong> While budesonide, a corticosteroid, is used in ulcerative colitis, it's generally reserved for more severe cases or when 5-ASA is ineffective. In a stable patient, it may not be the first choice.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. 6-Mercaptopurine:</strong> This is an immunosuppressant used in ulcerative colitis primarily for maintenance therapy or in patients who haven't responded to other treatments, not typically as a first-line treatment in a stable patient.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">5-Aminosalicylic acid (5-ASA) is the first-line treatment for mild to moderate ulcerative colitis and is effective in reducing inflammation and maintaining remission in stable patients experiencing active symptoms.</span></p>",
      "correct_choice_id": 127110,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31799,
      "choices": [
        {
          "id": 127066,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Initiate an insulin intravenous infusion at 0.1 units/kg/hour </span></span></span></p>"
        },
        {
          "id": 127067,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Give an insulin stat dose of 0.1 units/kg intravenously, followed by an infusion at 0.1 units/kg/hour </span></span></span></p>"
        },
        {
          "id": 127068,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Administer normal saline for the first hour followed by insulin infusion at 0.1 units/kg/hour </span></span></span></p>"
        },
        {
          "id": 127069,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#343541\">Continue with intravenous fluids without insulin administration</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:#343541\">A 10-year-old child with a known history of Type 1 Diabetes Mellitus presents to the emergency department with symptoms of increased thirst, frequent urination, abdominal pain, and confusion. On examination, the child appears dehydrated and is breathing rapidly. Laboratory tests reveal a blood glucose level of 400 mg/dl and blood gas analysis is indicative of acidosis. Initial treatment with intravenous fluids has been started. What is the most appropriate next step in the management of this patient? </span></span></span></p>",
      "unique_key": "Q7902893",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696039,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ans. C) <span style=\"color:#343541\">Administer normal saline for the first hour followed by insulin infusion at 0.1 units/kg/hour</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The clinical presentation is suggestive of diabetic ketoacidosis (DKA), which is an acute, life-threatening complication of diabetes mellitus that typically requires IV fluids and insulin administration to correct hyperglycemia and halt ketogenesis. According to latest guidelines for management of DKA in children first IV fulids are administered for one hour, then insulin is adminsitered by IV infusion at a rate of 0.1 U/kg/hour.&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other options:</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong> <strong>Give an insulin stat dose of 0.1 units/kg intravenously, followed by an infusion at 0.1 units/kg/hour:</strong> According to new guidelines, bolus dose of insulin is not used for treatment of DKA particularly in children as it increases the risk of cerebral edema in many children.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong> <strong>Initiate an insulin intravenous infusion at 0.1 units/kg/hour:</strong> While insulin infusion is an essential part of DKA management, according to new guidelines, it&#39;s typically given one hour after the adminsitration of IV fluids.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong> <strong>Continue with intravenous fluids without insulin administration:</strong> This would not address the hyperglycemia and ketosis and is therefore inadequate for the treatment of DKA.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">According to latest guidelines for management of DKA in children first IV fulids are administered for one hour, then insulin is adminsitered by IV infusion at a rate of 0.1 U/kg/hour.&nbsp;</span></span></p>",
      "correct_choice_id": 127068,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31821,
      "choices": [
        {
          "id": 127154,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Memantine </span></span></p>"
        },
        {
          "id": 127155,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Donepezil </span></span></p>"
        },
        {
          "id": 127156,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rivastigmine </span></span></p>"
        },
        {
          "id": 127157,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Galantamine</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 72-year-old patient with a confirmed diagnosis of mild to moderate Alzheimer&#39;s dementia has shown aversion and non-compliance to oral medications. The patient&#39;s caregiver reports difficulty in administering the oral drugs due to the patient&#39;s refusal to swallow pills. Considering the need for continued treatment, which of the following medications could be prescribed in a form that does not require oral administration?</span></span></p>",
      "unique_key": "Q3330988",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696031,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.</strong> <strong>C) Rivastigmine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rivastigmine is an acetylcholinesterase inhibitor used in the treatment of mild to moderate dementia in Alzheimer&#39;s disease. Unlike memantine, donepezil, and galantamine, rivastigmine has the advantage of being available in a transdermal patch form. The transdermal patch allows for continuous delivery of the medication through the skin, which is beneficial for patients who are non-compliant with oral medications or have difficulty swallowing pills.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Memantine: </strong>Memantine is used in moderate to severe dementia and is usually administered orally. To date, there is no alternative route of administration available for memantine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Donepezil: </strong>Donepezil is typically administered orally and is used in all stages of Alzheimer&#39;s disease. There is an orally disintegrating tablet form, but it still requires the ability to manage oral intake.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Galantamine: </strong>Galantamine is also used for mild to moderate Alzheimer&#39;s dementia and is administered orally. There is no non-oral formulation available for galantamine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In conclusion, for a patient who refuses oral medication, rivastigmine can be prescribed in a patch form, providing an alternative route of administration that ensures the patient can continue to receive their dementia management therapy.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For a patient with Alzheimer&#39;s dementia who refuses oral medication, rivastigmine can be prescribed in a transdermal patch form, providing an alternative route of administration that ensures the patient can continue to receive their dementia management therapy.</span></span></p>",
      "correct_choice_id": 127156,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31822,
      "choices": [
        {
          "id": 127158,
          "text": "<p><span style=\"font-size:12pt;\">BAL (British Anti-Lewisite)</span></p>"
        },
        {
          "id": 127159,
          "text": "<p><span style=\"font-size:12pt;\">Oximes</span></p>"
        },
        {
          "id": 127160,
          "text": "<p><span style=\"font-size:12pt;\">EDTA (Ethylenediaminetetraacetic acid)</span></p>"
        },
        {
          "id": 127161,
          "text": "<p><span style=\"font-size:12pt;\">Penicillamine</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 58-year-old patient presents with signs and symptoms suggestive of heavy metal toxicity. Laboratory investigations confirm the presence of heavy metal ions in the patient's bloodstream. The medical team is considering chelation therapy to bind and facilitate the excretion of the toxic metals. Which of the following agents is NOT typically used for the treatment of heavy metal toxicity? (</span><span style=\"background-color:rgb(255,255,255);color:rgb(111,126,149);font-size:14px;\">INICET Nov 2023)</span></p>",
      "unique_key": "Q1719101",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696032,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Oximes</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The agents listed are all chelating agents except for oximes, which are not typically used for heavy metal toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Oximes, such as pralidoxime, are used to reactivate acetylcholinesterase that has been inactivated by organophosphate poisoning, not heavy metal toxicity. They do not have a chelating effect on heavy metals and are therefore not used in the treatment of heavy metal toxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. BAL (British Anti-Lewisite): </strong>BAL is a chelating agent used to treat arsenic, gold, and mercury poisoning. It works by binding to the heavy metal ions, forming a complex that can be excreted from the body.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. EDTA (Ethylenediaminetetraacetic acid): </strong>EDTA is another chelating agent that binds to lead and other heavy metals. It is used in cases of lead poisoning and can also chelate other metals such as zinc, cadmium, and manganese.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Penicillamine: </strong>Penicillamine is used in the treatment of copper toxicity, such as Wilson's disease, and can also chelate mercury and lead. It binds to the metals and helps remove them from the body.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Oximes are not used for heavy metal chelation and are specifically used to treat organophosphate poisoning by reactivating acetylcholinesterase. Chelating agents like BAL, EDTA, and penicillamine are typically used for heavy metal toxicity.</span></p>",
      "correct_choice_id": 127159,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31803,
      "choices": [
        {
          "id": 127082,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intravenous doxycycline only </span></span></p>"
        },
        {
          "id": 127083,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intravenous doxycycline and ceftriaxone </span></span></p>"
        },
        {
          "id": 127084,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intravenous ceftriaxone and azithromycin </span></span></p>"
        },
        {
          "id": 127085,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Intravenous doxycycline and azithromycin</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 30-year-old woman with no significant past medical history presents to the emergency department with symptoms that have persisted for five days, including high-grade fever, severe headache, generalized body aches, and a new cough accompanied by mild shortness of breath. She also reports noticing a blackish lesion at the site of an insect bite on her thigh after returning from a camping trip in a region known for chigger infestation. On physical examination, she is found to have a fever of 39&deg;C, regional lymphadenopathy, and a well-defined eschar at the site of the lesion. Lung auscultation reveals mild diffuse rales. Laboratory tests show a normal white blood cell count and elevated liver enzymes. A chest X-ray indicates interstitial infiltrates, suggestive of atypical pneumonia that may be related to her primary infection. What is the most appropriate treatment for this patient?</span></span></p>",
      "unique_key": "Q8973195",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696043,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Intravenous doxycycline only.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The patient&#39;s clinical presentation is consistent with a rickettsial infection, likely contracted from a chigger bite, as evidenced by the eschar at the bite site, symptoms, and regional lymphadenopathy. The recommended treatment for rickettsial infections, such as scrub typhus, is doxycycline. This antibiotic is effective in treating the intracellular pathogens responsible for these infections. The additional symptoms of atypical pneumonia are also suggestive of a rickettsial etiology, which doxycycline can adequately address.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Intravenous doxycycline and ceftriaxone:</strong> Combining doxycycline with ceftriaxone could be considered if there was a high suspicion of a secondary bacterial infection, particularly one that is serious and requires broad-spectrum coverage such as ceftriaxone. However, the patient&#39;s presentation does not strongly indicate such a co-infection.</span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Intravenous ceftriaxone and azithromycin:</strong> This regimen is commonly used for community-acquired pneumonia with the intention to cover both typical and atypical pathogens. While the patient does exhibit signs of atypical pneumonia, the clinical findings are more suggestive of a rickettsial infection, which would not be optimally treated with this combination.</span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Intravenous doxycycline and azithromycin:</strong> Azithromycin could be added to doxycycline if there were concerns about atypical pneumonia due to pathogens like Mycoplasma pneumoniae or Chlamydophila pneumoniae. However, in the context of the patient&#39;s clinical presentation and recent exposure history, doxycycline alone should suffice to cover the likely rickettsial pathogen.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Doxycycline is the treatment of choice for rickettsial infections, such as those contracted from chigger bites, and is effective against both the primary infection and associated complications like atypical pneumonia.</span></span></li>\r\n</ul>",
      "correct_choice_id": 127082,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54783,
      "choices": [
        {
          "id": 218597,
          "text": "<p><span style=\"font-size:12.0pt;\">1 only</span></p>"
        },
        {
          "id": 218598,
          "text": "<p><span style=\"font-size:12.0pt;\">1 and 2</span></p>"
        },
        {
          "id": 218599,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, and 3</span></p>"
        },
        {
          "id": 218600,
          "text": "<p><span style=\"font-size:12.0pt;\">1, 2, and 4</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following are properties of ventricular muscle fibers: (INICET MAY 2024)</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\">All or none law</span></li><li><span style=\"font-size:12.0pt;\">Length-tension relation</span></li><li><span style=\"font-size:12.0pt;\">Tetanus</span></li><li><span style=\"font-size:12.0pt;\">Long refractory period</span></li></ol>",
      "unique_key": "Q3980314",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696051,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) 1, 2, and 4</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ventricular muscle fibers exhibit several unique properties that are crucial for their function:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>1. All or None Law</strong>: This principle states that a single muscle fiber will either contract fully or not at all in response to a stimulus. Ventricular muscle fibers act as a syncytium due to the presence of gap junctions made up of connexin proteins, which allows them to follow the all-or-none law. Thus, this property is true for ventricular muscle fibers.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>2. Length-Tension Relation</strong>: The length-tension relationship in ventricular muscle fibers is a reflection of the Frank-Starling law, which states that the force of contraction of the heart muscle is proportional to its initial length (or end-diastolic volume, EDV). This relationship is crucial for adjusting cardiac output based on the volume of blood returning to the heart. Within physiological limits, an increase in the initial length of the muscle fiber increases the force of contraction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>4. Long Refractory Period</strong>: Ventricular muscle fibers have a long refractory period due to the extended plateau phase in their action potential. This long refractory period is crucial in preventing tetanus and ensuring that the heart muscle relaxes fully before the next contraction, maintaining efficient pumping action.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Option:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>3. Tetanus</strong>: Tetanus is a sustained muscle contraction that occurs when the muscle is stimulated at a high frequency. However, due to the long refractory period in ventricular muscle fibers, tetanus is not possible. The plateau phase (phase 2) of the cardiac action potential is prolonged, which ensures that the heart muscle cannot be re-stimulated before the previous contraction is complete. This prevents sustained contractions (tetanus), which would be detrimental to cardiac function.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ventricular muscle fibers follow the all-or-none law, have a length-tension relationship (Frank-Starling law), and possess a long refractory period that prevents tetanus.</span></p>",
      "correct_choice_id": 218600,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31827,
      "choices": [
        {
          "id": 127178,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Furosemide </span></span></p>"
        },
        {
          "id": 127179,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Digoxin </span></span></p>"
        },
        {
          "id": 127180,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Captopril </span></span></p>"
        },
        {
          "id": 127181,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Carvedilol</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with symptoms of exertional and nocturnal dyspnea, cardiomegaly observed on imaging, pedal edema, a gallop rhythm on cardiac auscultation, and rales in both lungs. Based on this clinical presentation, which suggests congestive heart failure (CHF), which of the following drugs would be most appropriate to prevent the progression of the disease?</span></span></p>",
      "unique_key": "Q1985650",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696036,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) Captopril</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The patient&#39;s clinical presentation is consistent with heart failure, as indicated by symptoms such as dyspnea on exertion, nocturnal dyspnea, cardiomegaly, pedal edema, a gallop rhythm, and rales in the lungs. All the listed drugs can be used in the management of heart failure, but the question specifically asks about preventing the progression of the disease.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Captopril is an ACE inhibitor, which has been shown to be effective in reducing mortality and morbidity in patients with heart failure and in preventing the progression of heart failure. It works by decreasing afterload and preload, improving symptoms, and slowing the progression of heart failure.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Furosemide: </strong>Furosemide is a loop diuretic that is used to reduce the symptoms of fluid overload in heart failure, such as pedal edema and pulmonary congestion, but it does not have a significant impact on the progression of the disease.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Digoxin: </strong>Digoxin is a cardiac glycoside that can improve symptoms and cardiac function in heart failure but has not been shown to prevent the progression of the disease and is associated with significant toxicity.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Carvedilol: </strong>Carvedilol is a beta-blocker that has been shown to improve survival in heart failure. However, it is generally not used as a first-line therapy for acute exacerbation due to its initial negative inotropic effect, but it can be beneficial over the long term for improving cardiac function and reducing the risk of progression.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Captopril, an ACE inhibitor, is the best choice for preventing the progression of heart failure due to its effectiveness in reducing mortality and morbidity, decreasing afterload and preload, and improving symptoms and long-term outcomes in heart failure patients.</span></span></p>",
      "correct_choice_id": 127180,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54792,
      "choices": [
        {
          "id": 218633,
          "text": "<p><span style=\"font-size:12.0pt;\">PKA  cAMP  adenylyl cyclase</span></p>"
        },
        {
          "id": 218634,
          "text": "<p><span style=\"font-size:12.0pt;\">cAMP  Adenylyl cyclase  PKA</span></p>"
        },
        {
          "id": 218635,
          "text": "<p><span style=\"font-size:12.0pt;\">Adenylyl cyclase  cAMP  PKA</span></p>"
        },
        {
          "id": 218636,
          "text": "<p><span style=\"font-size:12.0pt;\">PKA Adenylyl cyclase  cAMP</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Select the correct sequence: (INICET MAY 2024)</span></p>",
      "unique_key": "Q7936851",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696044,
      "difficulty_level": "intermediate",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Adenylyl cyclase  cAMP  PKA</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The sequence involves the activation of a G protein-coupled receptor pathway. When a hormone binds to its receptor, the associated heterotrimeric G protein undergoes a conformational change. This change leads to the exchange of GDP for GTP on the G protein's alpha subunit, causing it to dissociate from the beta and gamma subunits.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The activated GTP-bound alpha subunit then interacts with adenylyl cyclase, an enzyme located on the inner membrane of the cell. Adenylyl cyclase converts ATP into cyclic AMP (cAMP). The newly formed cAMP acts as a secondary messenger that activates Protein Kinase A (PKA). PKA, in turn, phosphorylates various target proteins, leading to a cascade of cellular responses.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The correct sequence in the G protein-coupled receptor pathway is: Adenylyl cyclase activates the conversion of ATP to cAMP, which then activates Protein Kinase A (PKA).</span></p>",
      "correct_choice_id": 218635,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54797,
      "choices": [
        {
          "id": 218653,
          "text": "<p><span style=\"font-size:12.0pt;\">Estradiol</span></p>"
        },
        {
          "id": 218654,
          "text": "<p><span style=\"font-size:12.0pt;\">Estrone</span></p>"
        },
        {
          "id": 218655,
          "text": "<p><span style=\"font-size:12.0pt;\">Estriol</span></p>"
        },
        {
          "id": 218656,
          "text": "<p><span style=\"font-size:12.0pt;\">Conjugated estrogen</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Most potent biological Estrogen: (INICET MAY 2024)</span></p>",
      "unique_key": "Q6711566",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696049,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Estradiol</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Estrogens are a group of steroid hormones that play a crucial role in the regulation of the female reproductive system and secondary sexual characteristics. Among the different forms of estrogen, estradiol (E2) is the most potent and biologically active. Estradiol is primarily produced by the ovaries and is the dominant form of estrogen during the reproductive years.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Estradiol</strong> binds with the highest affinity to estrogen receptors compared to other forms like estrone and estriol, which is why it exerts the most potent biological effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Estrone</strong>: Estrone (E1) is less potent than estradiol and is the primary form of estrogen after menopause. It has a weaker affinity for estrogen receptors and thus, exerts less biological activity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Estriol</strong>: Estriol (E3) is the weakest of the three primary estrogens. It is primarily produced during pregnancy and has the least biological activity due to its low affinity for estrogen receptors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Conjugated estrogen</strong>: Conjugated estrogens are a mixture of several types of estrogens, typically used in hormone replacement therapy. They are not as biologically potent as estradiol when considered individually.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Estradiol is the most potent biological estrogen.</span></p>",
      "correct_choice_id": 218653,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31824,
      "choices": [
        {
          "id": 127166,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Empagliflozin </span></span></p>"
        },
        {
          "id": 127167,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Linagliptin </span></span></p>"
        },
        {
          "id": 127168,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rosiglitazone </span></span></p>"
        },
        {
          "id": 127169,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Insulin degludec</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with a history of diabetes mellitus presents with heart failure characterized by a reduced ejection fraction and low urine output. Which of the following anti-diabetic medications has been recently approved for the treatment of heart failure with reduced ejection fraction, and may also improve diuresis?</span></span></p>",
      "unique_key": "Q5699371",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696034,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Empagliflozin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that not only improves glycemic control in patients with type 2 diabetes but also has cardiovascular benefits. Recent clinical trials have shown that empagliflozin is effective in reducing the risk of cardiovascular death and hospitalization for heart failure in patients with heart failure with reduced ejection fraction (HFrEF), regardless of the presence or absence of diabetes. The diuretic effect of SGLT2 inhibitors, leading to increased urine output, may also contribute to the clinical benefit in heart failure patients by reducing fluid overload.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong> Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve blood sugar control in adults with type 2 diabetes, with no direct indication for heart failure.</span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong> Rosiglitazone is a thiazolidinedione that has been associated with fluid retention and is not indicated for patients with heart failure.</span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong> Insulin degludec is a long-acting insulin used to control high blood sugar in diabetes but does not have an indication for heart failure.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Empagliflozin, an SGLT2 inhibitor, is approved for the treatment of heart failure with reduced ejection fraction and provides cardiovascular benefits, including increased diuresis, which can help manage fluid overload in heart failure patients.</span></span></p>",
      "correct_choice_id": 127166,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54796,
      "choices": [
        {
          "id": 218649,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin</span></p>"
        },
        {
          "id": 218650,
          "text": "<p><span style=\"font-size:12.0pt;\">Thyroxine</span></p>"
        },
        {
          "id": 218651,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin-like growth factor</span></p>"
        },
        {
          "id": 218652,
          "text": "<p><span style=\"font-size:12.0pt;\">Growth hormone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which hormone is not responsible for intrauterine growth? (INICET MAY 2024)</span></p>",
      "unique_key": "Q4982764",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696048,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Growth hormone</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Growth hormone (GH) plays a crucial role in postnatal growth and development, but it is not significant during intrauterine (fetal) growth. During fetal development, the receptors for growth hormone are not sufficiently developed, which limits its ability to influence growth in utero. Instead, other hormones such as insulin, thyroxine, and insulin-like growth factors (IGFs) are critical for intrauterine growth.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Insulin</strong>: This hormone is essential for fetal growth as it promotes the storage of glucose and fats, providing energy for developing tissues.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Thyroxine</strong>: Thyroid hormones, particularly thyroxine, are crucial for both physical growth and brain development during fetal life.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Insulin-like Growth Factor (IGF)</strong>: IGFs, particularly IGF-2 during fetal life (and IGF 1 in adult life), play a significant role in promoting cellular growth and development. IGFs are produced in response to fetal pituitary signals but are the main drivers of growth, not GH itself.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Growth hormone is not responsible for intrauterine growth due to the underdeveloped nature of its receptors in the fetus, making insulin, thyroxine, and IGFs the primary hormones for fetal growth.</span></p>",
      "correct_choice_id": 218652,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31825,
      "choices": [
        {
          "id": 127170,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Stop pyrazinamide and continue the rest of the drugs with kidney function test (KFT) monitoring. </span></span></p>"
        },
        {
          "id": 127171,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Add uric acid-lowering drugs and continue antitubercular therapy (ATT) as such with liver function test (LFT) and KFT monitoring. </span></span></p>"
        },
        {
          "id": 127172,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Continue all drugs and monitor serum uric acid level as well as LFT and KFT. </span></span></p>"
        },
        {
          "id": 127173,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Stop all ATT drugs until laboratory values return to normal.</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A patient undergoing antitubercular therapy reports joint pain 10 days after initiation of treatment. Laboratory tests reveal normal AST and ALT levels, a serum creatinine of 0.9 mg/dL, and an elevated serum uric acid level of 10 mg/dL. What is the most appropriate next step in managing this patient&#39;s treatment?</span></span></p>",
      "unique_key": "Q9944495",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696035,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Stop pyrazinamide and continue the rest of the drugs with kidney function test (KFT) monitoring.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pyrazinamide is known to increase uric acid levels as a side effect, and hyperuricemia can lead to joint pain, which is suggestive of gout. If the patient&#39;s liver function tests are within normal limits, but they have elevated serum uric acid levels and are experiencing joint pain, the likely culprit is pyrazinamide.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Option A is the best next step because:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Stopping pyrazinamide, which is most likely causing the hyperuricemia, should lead to a decrease in uric acid levels and an improvement in joint pain.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The rest of the antitubercular drugs can be continued to ensure the treatment of tuberculosis, with monitoring of kidney function tests to ensure the patient does not develop nephrotoxicity.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Add uric acid-lowering drugs and continue antitubercular therapy (ATT) as such with liver function test (LFT) and KFT monitoring: </strong>Adding uric acid-lowering drugs might not be necessary immediately if pyrazinamide is discontinued. The primary goal is to identify and stop the drug causing the hyperuricemia.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Continue all drugs and monitor serum uric acid level as well as LFT and KFT: </strong>Continuing all drugs without modification might not address the underlying issue of hyperuricemia caused by pyrazinamide, potentially worsening the patient&#39;s symptoms.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Stop all ATT drugs until laboratory values return to normal: </strong>Stopping all ATT drugs would not be recommended as it could lead to the development of drug-resistant tuberculosis and could be harmful to the overall treatment of the disease.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pyrazinamide can cause hyperuricemia and joint pain; stopping pyrazinamide while continuing other antitubercular drugs with monitoring is the appropriate management strategy.</span></span></p>",
      "correct_choice_id": 127170,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31817,
      "choices": [
        {
          "id": 127138,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A</span></span></p>"
        },
        {
          "id": 127139,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">B</span></span></p>"
        },
        {
          "id": 127140,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">C</span></span></p>"
        },
        {
          "id": 127141,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">D</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the figure shown below, mechanism of action of valproate is best represented by:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/12/30/1.jpg\" style=\"height:302px; width:400px\" /></span></span></p>",
      "unique_key": "Q7047263",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696029,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) A</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mechanisms of Action of Sodium Valproate</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Enhancement of GABA Activity:</strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:disc\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate increases the levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain. This is achieved primarily by stimulating the enzyme glutamic acid decarboxylase that helps in formation of GABA from glutamic acid. Valproate also acts by inhibiting GABA transaminase, the enzyme responsible for GABA breakdown, leading to increased GABA availability.</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Inhibition of Voltage-Gated Sodium Channels:</strong></span></span>\r\n\t<ul style=\"list-style-type:disc\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate modulates voltage-gated sodium channels in the neurons. By prolonging the recovery of these channels from inactivation, valproate reduces the high-frequency repetitive firing of action potentials.</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Inhibition of T-Type Calcium Channels:</strong></span></span>\r\n\t<ul style=\"list-style-type:disc\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate also affects T-type calcium channels, particularly in thalamic neurons. By inhibiting these channels, it reduces the rhythmic cortical discharges that are often seen in absence seizures.</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong> B represents the mechanism of action of drugs like gabapentin and pregabalin. These act by increasing the release of GABA.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong> C represents the mechanism of action of tiagabine. It acts by inhibiting the reuptake of GABA.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong> D is site of action of benzodiazepines like diazepam and lorazepam.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Valproate increases GABA levels by stimulating the enzyme GAD (glutamic acid decarboxylase) to convert glutamate into GABA and by inhibiting GABA transaminase, preventing the breakdown of GABA.</span></span></p>",
      "correct_choice_id": 127138,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54795,
      "choices": [
        {
          "id": 218645,
          "text": "<p><span style=\"font-size:12.0pt;\">Pain</span></p>"
        },
        {
          "id": 218646,
          "text": "<p><span style=\"font-size:12.0pt;\">Touch</span></p>"
        },
        {
          "id": 218647,
          "text": "<p><span style=\"font-size:12.0pt;\">Two-point discrimination</span></p>"
        },
        {
          "id": 218648,
          "text": "<p><span style=\"font-size:12.0pt;\">Conscious proprioception</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The spinal trigeminal nucleus forms the second-order neuron of which of the following sensations? (INICET MAY 2024)</span></p>",
      "unique_key": "Q5930627",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696047,
      "difficulty_level": "intermediate",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Pain</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The spinal trigeminal nucleus is located in the medulla and functions as a relay center, particularly for pain and temperature sensations from the face. It processes these sensations and transmits the information to higher brain centers for interpretation. The second-order neurons in the spinal trigeminal nucleus specifically relay pain and temperature information, making it a critical component in the sensory pathway for these modalities.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The spinal trigeminal nucleus does not act as a relay center for other sensations like touch, two-point discrimination, or conscious proprioception.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Touch</strong>: The sensation of touch is primarily processed through other pathways, such as the dorsal columns and the main sensory nucleus of the trigeminal nerve, rather than the spinal trigeminal nucleus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Two-point discrimination</strong>: This sensation is typically processed by the dorsal column-medial lemniscus pathway, not the spinal trigeminal nucleus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Conscious proprioception</strong>: Conscious proprioception is also processed via the dorsal columns, particularly through the cuneate and gracile nuclei, and not the spinal trigeminal nucleus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The spinal trigeminal nucleus in the medulla serves as the second-order neuron relay center specifically for pain and temperature sensations from the face.</span></p>",
      "correct_choice_id": 218645,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31832,
      "choices": [
        {
          "id": 127198,
          "text": "<p><span style=\"font-size:12pt;\">Propranolol</span></p>"
        },
        {
          "id": 127199,
          "text": "<p><span style=\"font-size:12pt;\">Lugols Iodine</span></p>"
        },
        {
          "id": 127200,
          "text": "<p><span style=\"font-size:12pt;\">Acetaminophen</span></p>"
        },
        {
          "id": 127201,
          "text": "<p><span style=\"font-size:12pt;\">Aspirin</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">In the management of a thyroid storm, a critical and life-threatening condition due to an excess of thyroid hormone, a variety of medications are used to control the symptoms and the overactive thyroid. Which of the following drugs is not typically used in the treatment of thyroid storm?&nbsp;(INICET NOV 2023)</span></p>",
      "unique_key": "Q8018904",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696038,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Aspirin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Aspirin is avoided in thyroid storm because it can displace thyroid hormones from their binding proteins, potentially increasing the levels of active thyroid hormone in the blood and exacerbating the condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Thyroid storm is a severe hypermetabolic state caused by an excessive release of thyroid hormones (thyrotoxicosis). The standard treatment includes:</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Propranolol: </strong>Propranolol is a non-selective beta-blocker that is used to manage the sympathetic symptoms of thyrotoxicosis like tachycardia, tremors, and anxiety. It also inhibits the peripheral conversion of T4 to the more active T3.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Lugols Iodine: </strong>Lugol's Iodine is given to decrease the synthesis and release of thyroid hormones. The high iodine content temporarily inhibits the synthesis of thyroid hormones (the Wolff-Chaikoff effect) and blocks their release into the circulation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Acetaminophen: </strong>Acetaminophen (paracetamol) is preferred for fever control in thyroid storm. It does not have the anti-inflammatory properties that might interfere with thyroid hormone levels.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Aspirin is not used in the treatment of thyroid storm because it can increase free thyroid hormone levels by displacing thyroid hormones from their binding proteins, potentially worsening the condition.</span></p>",
      "correct_choice_id": 127201,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "INICET",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31801,
      "choices": [
        {
          "id": 127074,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Methadone </span></span></p>"
        },
        {
          "id": 127075,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Piperidine </span></span></p>"
        },
        {
          "id": 127076,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Morphine </span></span></p>"
        },
        {
          "id": 127077,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tramadol</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old male with a history of depression has been treated with fluoxetine for the past six months. He presented to the emergency department with altered consciousness and an ECG showing QT prolongation, with a QTc of 447 ms. Recently, he was prescribed an additional medication for chronic pain management. Which of the following drugs was most likely added to his regimen that could have contributed to his current condition?&nbsp;</span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q4140971",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696041,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Methadone</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Methadone</strong> is known to cause QT prolongation and can interact with fluoxetine, which is an SSRI and inhibits CYP450 enzymes, particularly CYP2D6, that metabolize many drugs including methadone. The inhibition can increase methadone levels, thus increasing the risk of QT prolongation and potential torsades de pointes.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong> <strong>Piperidine</strong> is not a drug but rather a chemical class that includes various analgesics, such as fentanyl and its analogs. These medications do not typically cause QT prolongation; therefore, this would not be the likely cause of the patient&#39;s altered consciousness associated with QT prolongation.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong> <strong>Morphine</strong> is an opioid analgesic but is not commonly associated with QT prolongation. It is less likely to be the cause of the EKG changes in the scenario provided.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Tramadol</strong> is a centrally acting opioid analgesic, which also inhibits the reuptake of serotonin and norepinephrine. It can potentially interact with fluoxetine, leading to increased serotonin levels and risk of serotonin syndrome. While it is less commonly associated with QT prolongation compared to methadone, it can still pose a risk, especially when combined with other drugs that affect serotonin levels or when overdosed.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Based on the clinical history and QTc value provided, methadone is the most likely cause of QT prolongation in this scenario, making option (a) the correct answer.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Methadone can cause QT prolongation, and when combined with fluoxetine, which inhibits its metabolism, the risk of QT prolongation and related cardiac issues increases significantly.</span></span></p>",
      "correct_choice_id": 127074,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31830,
      "choices": [
        {
          "id": 127190,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Linezolid: Binds to 30S ribosome and inhibits protein synthesis. </span></span></p>"
        },
        {
          "id": 127191,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin: Inhibits DNA-dependent RNA polymerase. </span></span></p>"
        },
        {
          "id": 127192,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Aztreonam: Inhibits cell wall synthesis. </span></span></p>"
        },
        {
          "id": 127193,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Daptomycin: Causes depolarization of membranes.</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Concerning the mechanism of action of various antimicrobial drugs, which of the following statements is FALSE?&nbsp;</span></span>&nbsp;(INICET Nov 2023)</p>",
      "unique_key": "Q5488899",
      "question_audio": null,
      "question_video": null,
      "map_id": 35696037,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A) Linezolid: Binds to 30S ribosome and inhibits protein synthesis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Linezolid is an oxazolidinone antibiotic that actually binds to the 50S subunit of bacterial ribosomes, not the 30S subunit. Its mechanism of action involves the inhibition of protein synthesis by preventing the formation of a functional 70S initiation complex, which is essential for bacterial translation.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong> <strong>Rifampicin:</strong> is indeed known to inhibit DNA-dependent RNA polymerase, which is critical for RNA synthesis in bacteria.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Aztreonam:</strong> is a monobactam antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins, thereby inhibiting peptidoglycan synthesis.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Daptomycin:</strong> causes depolarization of bacterial cell membranes, leading to the inhibition of all intracellular synthesis, including protein, DNA, and RNA synthesis, and ultimately cell death.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Linezolid binds to the 50S subunit of bacterial ribosomes, not the 30S subunit, making the statement that it binds to the 30S subunit and inhibits protein synthesis false. The other drugs mentioned have their mechanisms correctly stated.</span></span></p>",
      "correct_choice_id": 127190,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}